MedTrace Logo

Inspiratory Muscle Training in Difficult to Wean Patients

NCT03240263 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-10-09

No results posted yet for this study

Summary

Prolonged mechanical ventilation secondary to weaning failure demands a significant amount of intensive care unit (ICU) resources, thus increasing the economic burden of public healthcare costs. One of the proposed mechanisms accounting for weaning failure is the concept that excessive work of breathing for weak respiratory muscles during the liberation from mechanical ventilation compromises cerebral blood flow, thereby predisposing the brain to dysfunction. Restriction in brain perfusion could have an adverse impact on the function of the respiratory muscles by impairing the output of the respiratory centre thus promoting respiratory muscle fatigue, leading to weaning failure. Inspiratory muscle training (IMT) has been shown to improve the functional capacity of the inspiratory muscles in patients with respiratory muscle weakness whilst has been recently proposed as a possible additional component of weaning strategies. Therefore, this project aims to identify both a mechanism that might be linked to prolong ICU length of stay and that at the same time might be amenable to treatment.

Conditions

  • Weaning Failure

Interventions

PROCEDURE

Inspiratory Muscle Training

Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Resistance adjusted to the highest tolerable load. \*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK

PROCEDURE

Endurance training

Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Low training resistance adjusted to \<10% maximal inspiratory pressure. \*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK

Sponsors & Collaborators

  • KU Leuven

    lead OTHER

Principal Investigators

  • Rik Gosselink, PT, PhD · KU Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2023-08-01
Completion
2023-10-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03240263 on ClinicalTrials.gov